SLCO1B3 and hepatocellular carcinoma: Yi-Tian Chen found that NIFK-AS1 silencing could inhibit the proliferation, colony formation, and migration of hepatocellular carcinoma cells and sensitize tumor cells to sorafenib via upregulation of OATP1B1 and OATP1B3 (Chen et al., 2021).